BioMarin

View Complaint Frequently Asked Questions info@portnoylaw.com According to the lawsuit, throughout the Class Period the defendants made misleading and/or false statements and/or failed to disclose that: (1) GOL had material weaknesses in its internal controls; (2) there was substantial doubt as to the GOL’s ability to continue to operate as a going concern, as a...

0September 30, 2020September 30, 2020

9F

View Complaint Frequently Asked Questions info@portnoylaw.com On August 15, 2019, 9F conducted its IPO, selling over 8 million ADS shares at $9.50 per share. It is alleged in this complaint that the Registration Statement failed to disclose that 9F was in a dispute with PICC, its insurance partner, which resulted in multiple legal actions in...

0September 30, 2020September 30, 2020

Interface

View Complaint Frequently Asked Questions info@portnoylaw.com The investigation focuses on whether Interface issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Interface is the subject of an press release distributed by the SEC on September 28, 2020. This SEC release, titled, “Interface and Two Former Executives Charged With Accounting and Disclosure...

0September 30, 2020September 30, 2020

Semiconductor

View Complaint Frequently Asked Questions info@portnoylaw.com The investigation focuses on whether Semiconductor issued misleading and/or false statements and/or failed to disclose information pertinent to investors. SMIC is the subject of a report published by Reuters on September 26, 2020. According to the report, “The Trump administration is considering whether to add China’s top chipmaker SMIC...

0September 30, 2020September 30, 2020

Wrap

View Complaint Frequently Asked Questions info@portnoylaw.com According to the lawsuit, throughout the Class Period the defendants made misleading and/or false statements and/or failed to disclose that: (1) GOL had material weaknesses in its internal controls; (2) there was substantial doubt as to the GOL’s ability to continue to operate as a going concern, as a...

0September 25, 2020September 25, 2020

Fluadigm

View Complaint Frequently Asked Questions info@portnoylaw.com Fluidigm reported second quarter 2019 financial results in a press release issued on August 2, 2019. It was disclosed in this press release that Fluadigm reported revenue of $28.2 million, which is below analysts’ estimate of $32 million, and a net loss of $13.8 million. Fluadigm’s share price fell...

0September 23, 2020September 23, 2020

Huazhu

View Complaint Frequently Asked Questions info@portnoylaw.com The investigation focuses on whether misleading and/or false statements were made by Huazhu and/or that Huazhu failed to disclose pertinent information to investors. Huazhu is the subject of a report that was issued by Bonitas Research on September 21, 2020. Huazhu “lied about the ownership of its hotel portfolio...

0September 23, 2020September 23, 2020

Legend Biotech

View Complaint Frequently Asked Questions info@portnoylaw.com The investigation focuses whether false and/or misleading statements were made by Legend and/or that Legend failed to disclose pertinent information to investors. A press release was issued by Legend on September 21, 2020, which disclosed that Legend Biotech Corporation CEO Dr. Fangliang Zhang has been placed under residential surveillance...

0September 23, 2020September 23, 2020

Synchronoss

View Complaint Frequently Asked Questions info@portnoylaw.com On September 21, 2020, the Company announced that Glenn Lurie resigned as president/CEO and board member following the board’s review of allegations of personal misconduct in violation of the company’s policies. Following this news the Company’s shares fell significantly in value, thereby injuring investors. Synchronoss Technologies, Inc. Investors that...

0September 22, 2020September 22, 2020

Nano-X Imaging Ltd.

View Complaint Frequently Asked Questions info@portnoylaw.com A class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Nano-X Imaging Ltd. ("Nano-X" or the "Company") (NASDAQ: NNOX) securities during the period from August 21, 2020 through September 15, 2020 (the "Class Period")....

0September 18, 2020September 18, 2020